Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present).

IF 4.6 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2026-05-01 Epub Date: 2026-04-19 DOI:10.1080/13543776.2026.2660906

Xin-Yi Huang, Chao-Qun Yu, Xin Wang, Zhen Guo, Cheng-Hua Jin

{"title":"Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present).","authors":"Xin-Yi Huang, Chao-Qun Yu, Xin Wang, Zhen Guo, Cheng-Hua Jin","doi":"10.1080/13543776.2026.2660906","DOIUrl":null,"url":null,"abstract":"Introduction: Activin receptor-like kinase 5 (ALK5) is a pivotal component of the transforming growth factor β (TGF-β) signaling pathway. Currently, 10 ALK5 inhibitors are under clinical investigation, with numerous others in preclinical stages, demonstrating broad therapeutic potential. However, no systematic review of ALK5 inhibitor-related patents has been conducted to date. Therefore, this study systematically reviews patents related to ALK5 inhibitors from 2013 to the present, providing a theoretical basis for discovering structurally novel, safe, and effective ALK5 inhibitors.Areas covered: This paper briefly outlines ALK5 inhibitors currently in clinical development and ALK5-related patents published since 2013, retrieved through databases such as Google Patents, CAS SciFinder and PatSnap.Expert opinion: ALK5 inhibitors have garnered significant interest in recent years for the treatment of TGF-β-related diseases, with encouraging outcomes observed in clinical trials. However, certain structural classes have been associated with adverse effects such as cardiotoxicity and bone toxicity. This review consolidates patent literature on ALK5 inhibitors, offering insights to support the development of novel, highly efficient, and low-toxicity inhibitors with improved pharmacokinetic profiles.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"401-433"},"PeriodicalIF":4.6000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2026.2660906","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Activin receptor-like kinase 5 (ALK5) is a pivotal component of the transforming growth factor β (TGF-β) signaling pathway. Currently, 10 ALK5 inhibitors are under clinical investigation, with numerous others in preclinical stages, demonstrating broad therapeutic potential. However, no systematic review of ALK5 inhibitor-related patents has been conducted to date. Therefore, this study systematically reviews patents related to ALK5 inhibitors from 2013 to the present, providing a theoretical basis for discovering structurally novel, safe, and effective ALK5 inhibitors.

Areas covered: This paper briefly outlines ALK5 inhibitors currently in clinical development and ALK5-related patents published since 2013, retrieved through databases such as Google Patents, CAS SciFinder and PatSnap.

Expert opinion: ALK5 inhibitors have garnered significant interest in recent years for the treatment of TGF-β-related diseases, with encouraging outcomes observed in clinical trials. However, certain structural classes have been associated with adverse effects such as cardiotoxicity and bone toxicity. This review consolidates patent literature on ALK5 inhibitors, offering insights to support the development of novel, highly efficient, and low-toxicity inhibitors with improved pharmacokinetic profiles.

查看原文本刊更多论文

激活素受体样激酶5 （ALK5）抑制剂：专利审查（2013年至今）。

激活素受体样激酶5 （ALK5）是转化生长因子β (TGF-β)信号通路的关键组成部分。目前，有10种ALK5抑制剂正处于临床研究阶段，其他许多抑制剂处于临床前阶段，显示出广泛的治疗潜力。然而，迄今为止尚未对ALK5抑制剂相关专利进行系统综述。因此，本研究系统回顾了2013年至今与ALK5抑制剂相关的专利，为发现结构新颖、安全有效的ALK5抑制剂提供理论依据。涵盖领域：本文简要概述了目前处于临床开发阶段的ALK5抑制剂和2013年以来公布的ALK5相关专利，这些专利可通过谷歌patents、CAS SciFinder和PatSnap等数据库检索。专家意见：近年来，ALK5抑制剂在TGF-β相关疾病的治疗中引起了极大的兴趣，在临床试验中观察到令人鼓舞的结果。然而，某些结构类型与诸如心脏毒性和骨毒性等不良反应有关。本综述整合了有关ALK5抑制剂的专利文献，为开发新型、高效、低毒且具有改善药代动力学特征的抑制剂提供了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.